Lv3
270 积分 2022-01-26 加入
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
21小时前
待确认
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
21小时前
已完结
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer
23天前
已关闭
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer
23天前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
1个月前
已完结
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
1个月前
已关闭
Breast cancer in China
1个月前
已完结
The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients
1个月前
已完结
ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
1个月前
已完结
Expression of Concern—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
1年前
已采纳
An anti-apoptosis gene, survivin and telomerase expression in gastric cancer
2年前
已采纳
SGA-born adults with postnatal catch-up have a persistently unfavourable metabolic health profile and increased adiposity at age 32 years
2年前
已采纳
Update on Staphylococcus aureus bacteraemia
2年前
已采纳
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care
2年前
已采纳
Cancer Conformational Landscape Shapes Tumorigenesis
2年前
已驳回
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
2年前
已采纳
皖公网安备34019202002308
